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SurvivalObjective.Main controversies in endometrial cancer treatment include the role of lymphadenectomy and op-
timal adjuvant treatment. We assessed clinical outcome in a population-based endometrial cancer cohort in re-
lation to changes in treatment management over two decades.
Methods. All consenting endometrial cancer patients receiving primary treatment at Haukeland University
Hospital from 2001 to 2019 were included (n = 1308). Clinicopathological variables were evaluated for year-
to-year changes. Clinical outcome before and after discontinuing adjuvant radiotherapy and individualizing ex-
tent of lymphadenectomy was analyzed.
Results. The rate of lymphadenectomywas reduced from 78% in 2001–2012 to 53% in 2013–2019. The rate of
patientswith verified lymph nodemetastaseswasmaintained (9% vs 8%, p=0.58) and FIGO stage I patientswho
did not undergo lymphadenectomy had stable 3-year recurrence-free survival (88% vs 90%, p=0.67). Adjuvant
chemotherapy for completely resected FIGO stage III patients increased from 27% to 97% from 2001 to 2009 to
2010–2019, while adjuvant radiotherapy declined from 57% to 0% (p < 0.001). These patients had improved 5-
year overall- and recurrence-free survival; 0.49 [95% CI: 0.37–0.65] in 2001–2009 compared to 0.61
[0.45–0.83] in 2010–2019, p = 0.04 and 0.51 [0.39–0.68] to 0.71 [0.60–0.85], p = 0.03, respectively. For stage
I, II and IV, survival rates were unchanged.
Conclusions.Our study demonstrates that preoperative stratification by imaging and histological assessments
permits a reduction in lymphadenectomy to around 50%, and is achievable without an increase in recurrences at
3 years. In addition, our findings support that adjuvant chemotherapy alone performs equally to adjuvant radio-
therapy with regard to survival, and is likely superior in advanced stage patients.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
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Endometrial cancer is the most common gynecological cancer in in-
dustrialized countries,with a cumulative lifetime risk of 2–3% inwomen
[1,2]. The prognosis in endometrial cancer is generally good due to
detection at an early stage where surgery is likely curative [3]. Thus,
selecting an appropriate level of treatment that balances the risk of
recurrence with the risk of iatrogenic morbidity is a major challenge.er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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sue dissection for staging and selecting optimal adjuvant treatment reg-
imens [4,5]. As an extensive research effort is ongoing to address these
topics, oncological centers develop local, national or international
guidelines, based on their respective evaluation of scientific evidence,
available resources and clinical tradition.
During the last decade, several changes in patient treatment have
been implemented for endometrial cancer patients in our region. In
2009national guidelineswere changed; adjuvant radiotherapy (external
beam +/− brachytherapy) was no longer recommended for patients
with high-risk tumors, defined as FIGO (International Federation of Gy-
necology and Obstetrics) stage IB grade 3 endometrioid, all stage I non-
endometrioid, and completely resected stage II-III [6]. Instead adjuvant
platinum based chemotherapy was advocated for all high-risk tumors,
motivated by emerging data suggesting better survival outcome
when opting for chemotherapy in the adjuvant setting [7]. In 2009 and
2011 respectively, pelvic magnetic resonance imaging (MRI) and
fluorodeoxyglucose-positron emission tomography/computed tomogra-
phy (PET/CT) were gradually integrated in preoperative diagnostics at
Haukeland University Hospital. Finally, in October 2015, the MoMaTEC2
study (Molecular Markers in the Treatment of Endometrial Cancer,
ClinicalTrials.gov Identifier: NCT02543710) was launched, evaluating
the implementation of estrogen and progesterone receptor (ER/PR) ex-
pression in preoperative biopsies in combination with histological
subtyping and imaging, with the intent to reduce the rate of patients un-
dergoing lymphadenectomy.
The aim of this study was to assess effects and outcome when
discontinuing adjuvant radiotherapy and reducing the rate of patients
undergoing lymphadenectomy through more extensive preoperative
patient stratification. Additionally, we explored trends in clinical and
pathological variables that could affect patient outcome during the ob-
served period.2. Methods
2.1. Ethical considerations
The study was approved by the Western Regional Committee for
Medical and Health Research Ethics (REK 2009/2315, 2018/594, and
2019/1020). All included patients signed an informed consent.2.2. Patient series
HaukelandUniversity Hospital serves approximately 10% of theNor-
wegian gynecological population as a full-scale gynecological oncology
center, providing treatment for all endometrial cancer for local patients.
Additionally, the center receives high-risk/advanced stage patients from
neighboring counties, comprising approximately 15% of the cohort. The
population of Hordaland is demographically representative of the Nor-
wegian population, with similar distributions of age, gender, and body
mass index (BMI) [8].
All consentingpatients referred toHaukelandUniversity Hospital for
primary treatment of endometrial cancer from 2001 to 2019 were in-
cluded. Patients were surgically staged according to FIGO 2009 criteria;
patients treated prior to 2009 were reclassified according to the 2009
criteria as previously described [9]. Clinical and pathological variables
were collected from the medical records. Radiological findings were
recorded based on the radiology report. The surgery- and multidisci-
plinary tumor board reports were also reviewed to record how radio-
logical findings had been perceived prior to surgery and to identify
reasons for performing or not performing lymphadenectomy. The imag-
ing protocols employed at our institution are largely in linewith recom-
mended European guidelines for preoperative imaging in endometrial
cancer [10].3972.3. Treatment
Standard treatment was hysterectomy with bilateral salpingo-
oophorectomy. Indications for lymphadenectomy changed over the
study period (see below). Omentectomy was performed in patients
with serous and clear cell tumors. All hysterectomies were performed
by laparotomy until the introduction of robotic-assisted laparoscopic
hysterectomy in 2010 and conventional laparoscopy in 2013 for se-
lected patients (manageable comorbidity, no presumed extrauterine
disease, and para-aortic lymphadenectomy not planned for). In the pal-
liative setting, treatment options included debulking, hysterectomy for
symptom control, or primary non-surgical therapy (chemotherapy, ra-
diotherapy, or hormonal therapy). Treatment decisions were made at
tumor board meetings including specialists in gynecological oncology,
oncology, radiology, and pathology.
2.4. Indications for lymphadenectomy
Indications for lymphadenectomy changed during the observation
period from a general pelvic sampling policy (sampling pelvic nodes
at the surgeon's discretion unless deemed not tolerable or restricted ac-
cess perioperatively) to a selective policy based on preoperative risk as-
sessment. Preoperative low-, intermediate-, and high-risk groups were
defined by histological assessment of curettage/endometrial biopsy
and radiological findings according to the European Society of Medical
Oncology (ESMO) guideline [11]. Low risk was defined as endometrioid
endometrial cancers grade 1–2 with <50% myometrial invasion (MI)
assessed by MRI, intermediate risk as endometrioid grade 1–2 with
MI > 50%, or grade 3 endometrioid with MI <50%. Endometrioid
grade 3 tumors with MI > 50% and all non-endometrioid cancers were
classified as high risk. The evaluation of myometrial invasion was non-
systematically performed by CT or ultrasound prior to the implementa-
tion of MRI in 2009, after which all patients were systematically
grouped. Pelvic lymphadenectomy was gradually restricted (2010
−2012) to the intermediate-risk group while pelvic and para-aortic
lymphadenectomy was performed for the high-risk group. In 2011,
PET/CT was introduced for preoperative evaluation. Any patient with
PET-positive pelvic or para-aortic lymph nodes underwent lymphade-
nectomy, unless intolerable or complete debulking was deemed
unattainable. In October 2015, preoperative immunohistochemical
expression of PR and ER was included as part of a phase 4 implementa-
tion study (MoMaTEC2); in low- and intermediate-risk cases, lymphad-
enectomy was omitted when ER and PR expression was positive. In
addition to preoperative assessment, perioperative findings (e.g. en-
larged lymph nodes) could prompt lymphadenectomy. Supplementary
Table 1 shows the current algorithm for extent of surgery.
2.5. Adjuvant treatment
Patients were postoperatively reclassified based on histopathologi-
cal examination of the hysterectomy specimen and final FIGO stage
into low-, intermediate-, or high-risk groups (endometrioid grade 3
stage IB, any stage II-IV tumors and any non-endometrioid tumors), in
line with the ESMO classification [11,12]. At Haukeland University Hos-
pital, lymphovascular space invasion status was added to the pathology
report in 2018, but did not affect treatment, and is not included in our
analyses. Standard adjuvant treatment in 2001–2009 was adjuvant ra-
diotherapy (external beam+/− brachytherapy) or platinum based ad-
juvant chemotherapy (standard being carboplatin plus paclitaxel for six
cycles) for high-risk tumors. The contemporary guidelines contained no
specification for choice of modality, except for a preference for chemo-
therapy in serous or clear-cell tumors. From 2009, national guidelines
no longer recommended adjuvant radiotherapy except for stage II pa-
tients with incomplete surgical margins. Instead, adjuvant chemother-
apy was advocated for all high-risk tumors, with six cycles of
carboplatin plus paclitaxel as standard treatment.
Table 1
Clinical and pathological characteristics of the cohort (n = 1308).
Median Interquartile range
Age at treatment 66 15






Para 0 208 16.1%
Para 1+ 1086 83.9%
Primary treatment
Hysterectomy 1241 94.9%
Tumor reduction 8 0.6%
Curettage 59 4.5%
Mode of surgery (hysterectomy)
Laparotomy 972 78.3%
Laparoscopy 92 7.4%
Robot-assisted laparoscopy 177 14.3%
Lymph node sampling
Not performed 422 32.3%
Pelvic 742 56.7%










Endometrioid (EEC) 1016 77.7%
Non-endometrioid 292 22.3%
Clear cell 50 3.8%
Serous papillary 148 11.3%
Carcinosarcoma 58 4.4%
Undifferentiated/other 36 2.8%
Histological Grade (EEC only)
Grade 1–2 826 82.8%
Grade 3 172 17.2%
Adjuvant treatment
None 863 66.0%
External radiation 81 6.2%
Brachytherapy 7 0.5%
Chemotherapy 325 24.8%
Chemotherapy + radiation 10 0.8%
Hormonal treatment 22 1.7%
FIGO International Federation of Gynecology and Obstetrics.
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All statistical analyseswere performed in SPSS 25.0 (IBM, NewYork)
or R v3.6.1 (R Core Team 2019). Year-to-year time trendswere assessed
by linear regression for continuous variables and the Chi-square test for
trend for proportions. Categorical variables were compared by
Chi-square test or Fischer's exact test, and differences in distributions
of continuous variables were assessed by the Mann-Whitney U test. To
explore the influence of clinicopathologic variables over the observation
period, a multivariable cox regression survival model was built using
enter method. Age, BMI, parity, MI, histological type and grade, FIGO
stage, year of treatment and adjuvant treatment modalities were ana-
lyzed in univariable analysis. Variables with hazard ratios with p < 0.1
were included in the adjusted multivariable analysis.
To compare different adjuvant treatment strategies the cohort was
divided at 01 Jan 2010, based on the time point for national guideline
change in 2009. For analysis of outcomes related to the systematic re-
duction in the rate of patients undergoing lymphadenectomy, 01 Jan
2013 was chosen, based on the time point where patient surgical files
started containing explicit rationale for performing lymphadenectomy
(gradual increase over 2010–2012).
Overall survival (OS) was defined as time from treatment to death
from any cause. Disease specific survival (DSS) was defined as time
from treatment to death from endometrial cancer. Recurrence-free Sur-
vival (RFS)was defined as time from surgery tofirst verified recurrence,
and only included patients with completely resected tumors (macro-
scopically tumor-free). To account for differences in follow-up times
due to sampling groups from different time periods, OS and DSS were
reported at 5 years after primary treatment longer follow-up was
blinded. RFS was analyzed at 3 years and follow-up was blinded at 3
years, as more than 70% of recurrences occur within 3 years, allowing
earlier reliable assessment of RFS than OS and DSS [13]. The Kaplan-
Meier method was used to visualize differences in survival between
groups, using the log-rank test for comparisons between groups. For
all statistical analyses, differences were considered significant at
p < 0.05 (two-sided).
3. Results
3.1. Increasing age, BMI and serous histology over time
A total of 1308 patients were included in the study (Table 1), with a
median follow-up time of 49 months (range 0–212). The number of
treated patients showed an increasing trend over 2001–2019, mirroring
the Norwegian increase in endometrial cancer incidence (Fig. 1A, Sup-
plementary Table 2). Median age at primary treatment was 66 years
(interquartile range 15), with an average 2 months/year increase
(p = 0.008, Fig. 1B). Median BMI was 27.3 kg/m2 (interquartile range
8), also with a slightly increasing trend over time (0.08 kg/m2/year,
p = 0.037, Fig. 1C). The distribution of FIGO stages showed some year-
to-year variation, but no time-dependent trend was observed
(Fig. 1D). The proportion of endometrioid endometrial cancer at post-
operative histopathological diagnosis was stable, as well as histological
grade within the endometrioid subtype (Fig. 1E and F). Distribution of
non-endometrioid histological typeswas constant, apart from a statisti-
cally significant increasing trend in the proportion of serous endome-
trial cancer (p = 0.004, Fig. 1E). The proportion of serous tumors in
2010–2019 was 13%, compared to 9% in 2001–2009 (Fig. 1F).
In a Cox regression model (Supplementary Table 3), increasing age,
stage III-IV, high grade EEC, NEEC, and deep myometrial invasion were
all significant predictors of poor survival in both unadjusted analysis
and after adjusting for all other variables (p = 0.031 for grade 3 EEC,
p<0.001 for the rest,). Year of primary treatment did not affect survival
outcome. Any adjuvant treatment was associated with higher hazard
ratio (for disease specific death) compared to no adjuvant treatment,
howeverwhen adjusting for the other variables, radiotherapy remained398significant with an adjusted hazard ratio of 1.9 (95% CI 1.1–3.4, p =
0.035), whereas chemotherapy did not (1.2, 95% CI 0.8–1.9, p = 0.47).3.2. Reduction of lymphadenectomy with maintained rate of stage IIIC
patients
MRI and PET/CT were implemented in diagnostics during the study
period (Fig. 1G), peaking in 2015–2019with>85% of patients subjected
to both examinations. The rate of lymphadenectomy decreased, with a
pronounced decline in 2012–2013, and flattening out to 50–60% on-
wards (Fig. 1H). Thus, a significantly smaller proportion of patients
underwent lymphadenectomy in 2013–2019 compared to 2001–2012
(53% versus 78%, p < 0.001). The rate of para-aortic procedures in-
creased (5% to 20% of all patients, p < 0.001) (Table 2). The rate of pa-
tients with verified lymph node metastases was stable across the two
time periods (8% vs 9%, p = 0.576), including para-aortic metastases
(Stage IIIC2; 2% vs 2%).
The group of patients not undergoing lymphadenectomy in
2013–2019 largely consisted of low- and intermediate-risk patients
(based on preoperative histology and MI) without additional risk
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Table 2
Comparison of extent of disease and extent and outcome of lymphadenectomy before and
after 1 Jan 2013.
2001–2012 2013–2019 p (chi-square)
(n = 778) (n = 530)
n (%) n (%)
FIGO Stage 0.899
I 581 (75) 384 (73)
II 60 (8) 41 (8)
III 91 (12) 66 (13)
IIIc1 49 (6) 30 (6)
IIIc2 14 (2) 9 (2)
IV 46 (6) 35 (7)
Lymphadenectomy (LA) <0.001
Not performed 171 (22) 251 (47)
Pelvic 567 (73) 175 (33)
Para-aortic and pelvic 40 (5) 104 (20)
Lymph node metastasis 0.576
Negative + unknown 708 (91) 487 (92)
Positive 70 (9) 43 (8)
FIGO: International Federation of Obstetrics and Gynecology.
Numbers in bold signify p-values < 0.05.
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upstaging) (Fig. 2A). Interestingly, among patients undergoing lymph-
adenectomy in this period, no patients had verified lymph node metas-
tases in the low- and intermediate-risk groups unless having additional
risk factors. Among non-lymphadenectomized low-risk patients, five
out of 79 (6%) experienced recurrence within 3 years, compared to
one of 25 (4%) of patients undergoing lymphadenectomy in spite of
not having any apparent risk factors. Corresponding percentages for
intermediate-risk patients without additional risk factors were four re-
currences in 41 node negative patients (10%) and three recurrences in
43 non-lymphadenectomized patients (7%).
Survival data was available for 778 patients treated between 2001
and 2012 with a median follow-up of 71 months (range 0–212) and
for 530 patients treated between 2013 and 2019 in with a median
follow-up of 25 months (range 0–70). Although the proportion of
stage I patients not undergoing lymphadenectomy increased from 17%
to 51%, 3-year RFS was maintained in this group (0.91 (95% CI
0.86–0.96) for 2013–2019 compared to 0.88 (95% CI 0.82–0.95), p =
0.46, Fig. 2B). For the whole cohort comparing 2001–2012 to
2013–2019, 3-year RFS was 0.84 (95% CI 0.81–0.87) vs 0.85 (95% CI
0.81–0.89, p = 0.56).3.3. Changes in adjuvant treatment with discontinuation of radiotherapy
Administration of adjuvant radiotherapy was reduced from 12% of
all patients in 2001–2009 to 1% in 2010–2019 (p < 0.001, Fig. 3A),
while the proportion of patients receiving adjuvant chemotherapy in-
creased from 10% to 31% (p < 0.001). In stage I high-risk patients, 79%
received chemotherapy in 2010–2019 compared to 28% in 2001–2009
(p < 0.001), representing the main contribution to the overall increase
in use of adjuvant therapy (Fig. 3B). For (postoperative) low- and
intermediate-risk patients in stage I, adjuvant therapy rates were low
and stable. In stage II patients, the reduction in radiotherapy was com-
parable to the increase in chemotherapy, thus with a stable overall
rate of adjuvant treatment in this group (62% to 58%, p=0.7). The pro-
portion of patientswith stage III (macroscopically tumor-free) receiving
adjuvant chemotherapy increased significantly from 27% to 95%
(p < 0.001). The proportion not receiving any adjuvant treatment in
this group decreased from 16% to 5% (p < 0.05).
The median follow-up time was 73 months (range 0–212) for the
2001–2009 group and 35 months (range 0–95) for the 2010–2019
group. No differences in 5-year OS or DSS between groups were
found, nor for 3-year RFS (Fig. 4A). In subgroup analysis, 5-year OS im-
proved significantly in completely resected stage III patients from 0.49
(95% CI: 0.37–0.65) to 0.61 (0.45–0.83, p = 0.04, Fig. 4B). RFS at
3 years in stage III was also significantly better in 2010–2019 (0.71
(95% CI: 0.39–0.68)) compared to the 2001–2009 group (0.51
(0.39–0.68, p=0.03)). OS, DSS and RFS in stage I and II were similar be-
fore and after 2009. Outcome was also stable for stage I high-risk pa-
tients in spite of a substantial increase in adjuvant chemotherapy in
this group (Supplementary Fig. 1). The 3-year recurrence rate for all pa-
tients for the whole observation period was 17%, with distant recur-
rences in 9%, pelvic in 2% and vaginal recurrences in 6% (Fig. 4C). In
completely resected stage III patients the rate of distant recurrences de-
creased from 38% in 2001–2009 to 28% in 2010–2019, vaginal recur-
rences from 9% to 3% and pelvic recurrences increased from 5% to 8%,
but the changes were not statistically significant.Fig. 1. Time trends in clinicopathological characteristics 2001–2019. A)Number of endometrial
lines show the incidence in Norway divided by 10 and the Norwegian age-standardized rate p
plementary Table 1. B) Age at primary treatment, median and inter-quartile range with linear
regression y= Bx+ k. D) Trend in distribution of FIGO stages. Trends analyzedwith chi-square
imen. Trends analyzed with chi-square test for trend. F) Distribution of histologic types in fina
subtypes. G) Changes in the use ofmagnetic resonance imaging (MRI) and positron emission to
from 2009, PET/CT from 2011. H) Changes in rates of lymphadenectomy, and extent of proced
4004. Discussion
Major research efforts are being deployed into uncovering the opti-
mal ways to stage and treat endometrial cancer. Main points of contro-
versy are the role of lymphadenectomy andmatching optimal adjuvant
therapy regimes to subgroups.We have performed a broad analysis in a
population based Norwegian cohort to retrospectively assess the effects
of national and local changes to optimize the rate of patients undergoing
lymphadenectomyon onehand, and the discontinuation of adjuvant ra-
diotherapy on the other. We describe a successful reduction of the rate
of endometrial cancer patients undergoing lymphadenectomy, with
maintained identification rates of stage IIIC patients and consistent
low recurrence rates in unstaged patients. In addition,we have analyzed
outcome after discontinuing radiotherapy as an adjuvant option and
implementing adjuvant chemotherapy alone as standard treatment in
high-risk patients, and find maintained overall survival outcome and
improved survival in stage III patients.
Sentinel node (SN)mapping is on the rise in endometrial cancer, due
to high sensitivity and negative predictive value [14]. Nevertheless, in a
recent survey, 50% of gynecological oncologists in Europe and USA did
not use this technique, implying that for many institutions a better
risk-stratification of patients prior to surgical staging is still an impor-
tant issue [15]. At our institution, where sentinel node mapping is not
implemented, the rate of patients undergoing lymphadenectomy has
decreased over the last 6–7 years. This is due to a shift from universal
sampling to selective lymphadenectomy, following an incorporation of
imaging and molecular biomarkers into the diagnostic work-up. We
show that in spite of a marked reduction in lymphadenectomies, we
still identifymetastatic nodes at the same rate, and there is no indication
of increased recurrence rates in the non-staged patients. For institutions
using sentinel node techniques, these results may also be of interest, es-
pecially when failed mapping mandates a full- or hemipelvic lymphad-
enectomy [16]. Even when successful, sentinel node procedures add
significant time and cost to surgery compared to no lymph node re-
moval, and should be omitted when unnecessary [17].cancer patients receiving primary treatment atHaukelandUniversity Hospital. The stippled
er 100,000 person years (ASR) based on 2014 age weights [2]. Full numerical data in Sup-
regression y = Bx + k. C) Body mass index, median and inter-quartile range with linear
test for trend. E) Trend in distribution of histopathological subtypes in final surgical spec-
l surgical specimen split by decade. Other includes undifferentiated and rare histological
mography/computerized tomography (PET/CT). MRI was included in routinemanagement
ure.
Fig. 2. A) Preoperative characterization of hysterectomized patients, before and after 01 Jan 2013, with a preoperative endometrial cancer assessment (excluding incidental findings after
benign diagnosis and surgery for presumed ovarian cancer). Inner circle displays risk groups based on histologic assessment of preoperative biopsy/curettage and imaging: Low:
endometrioid grade 1–2 with <50% myometrial invasion (MI) or MI unknown. Intermediate: endometrioid grade 1–2 with >50% MI or grade 3 with <50% MI. High: endometrioid
grade 3 with >50% MI or MI unknown and all non-endometrioid cancers. Patients missing preoperative histological info were excluded (n = 31). Second circle displays the additional
risk factor most important for explaining whether patients underwent LA, based on patient file review. Third circle displays prevalence of metastatic lymph nodes where LA was
performed. Outer circle displays recurrences or progression occurring within 3 years. All sectors correspond to proportions of patients included. ER Estrogen Receptor, PR Progesterone
Receptor, pre/perioperatively upstaged signifies imaging or clinical findings corresponding to stage>I (other than lymphadenopathy), technical signifies perioperative technical issues
due to adhesions, bleeding, also including patient's wish. B) Kaplan-Meier survival curve showing 3-year recurrence free survival before and after reduction of lymphadenectomies in
2013. FIGO: International Federation of Gynecology and Obstetrics.
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patients (stage I high-risk + stage II and III), and a concomitant cessation
of adjuvant radiotherapy. Although adjuvant therapy for high-risk pa-
tients is in line with current international recommendations, the optimal
treatment algorithm is under debate, especially concerning the respective
roles of radiotherapy and systemic chemotherapy. The ESMO consensus
favors external beam radiation therapy for stage I high-risk patients
when staged and node negative, and supports consideration of brachy-
therapy, but states that the role of systemic chemotherapy is insufficiently
investigated [12]. In trials with stage I high-risk patients where chemo-
therapy alone has been compared with radiotherapy, no differences in
OS or RFS have been shown, although pelvic recurrence rates were
lower after radiotherapy and distant recurrences lower after chemother-
apy [18,19]. Our study shows that omitting radiotherapy in stage I401patients has not produced poorer outcome, when substituted with che-
motherapy. Advantages with this approach is avoidance of radiotherapy
related side effects and saving radiotherapy for salvage treatment of vag-
inal and small pelvic recurrences in patients if they do occur. We report a
vaginal recurrence rate of 6% in thewhole population-based series, which
seems comparable to 5–10% in previously published chemotherapy only-
studies reporting high-risk cases [18–20].We do note that the substantial
increase in adjuvant chemotherapy in stage I patients does not seem to
improve outcome. The ongoing ENGOT-EN2-DGCG/EORTC55102 study
(clingov ID NCT01244789), comparing adjuvant chemotherapy with ob-
servation for low-stage high-risk patients will hopefully provide addi-
tional data to optimize treatment strategies for this group. Molecular
subtyping provides prognostic information independent of classical histo-
pathological stratification and could improve tailoring of treatment [21].
Fig. 3. A) Changes in administration of adjuvant treatment between 2001 and 2009 and 2010–2019. Hysterectomized patients with macroscopically resectable tumors included. Other
includes hormonal treatment (n = 5), brachytherapy alone (n = 2) and chemoradiation (n = 1). Statistical comparison between use of chemotherapy/radiotherapy in the different
time periods by Chi-square or Fischer's exact test (2-sided) where appropriate. B) Stage I risk groups based on histologic assessment of preoperative biopsy/curettage: low;
endometrioid grade 1–2 with <50% myometrial invasion (MI) or MI unknown, intermediate; endometrioid grade 1–2 with >50% MI on imaging or grade 3 with <50% MI, and high;
endometrioid grade 3 with >50% MI or MI unknown and all non-endometrioid cancers. FIGO: International Federation of Gynecology and Obstetrics.
D. Forsse, H.F. Berg, O. Bozickovic et al. Gynecologic Oncology 160 (2021) 396–404As of yet, no published prospective data regarding management of endo-
metrial cancer by molecular subtype is available.
Unlike early stage endometrial cancer, for advanced endometrial
cancer patients there is strong evidence in favor of adjuvant chemother-
apy. In the GOG-122 trial, chemotherapy demonstrated superior OS and
progression-free survival to radiotherapy for stage III-IV patients, and
was non-inferior to the combination of chemotherapy and radiotherapy
in GOG-258, although the pelvic recurrence rate was higher for chemo-
therapy alone [7,22]. In the present study, improvement in OS and RFS
for stage III patients was observed, coinciding with an overall increase
in adjuvant treatment, and at the same time a cessation of radiotherapy.
Similar survival and recurrence rates have been demonstrated in a sep-
arate Norwegian high-risk cohort [20]. The low rate of vaginal recur-
rences in stage III patients is interesting. However, a low number of
stage III patients could affect this result, and the drop from 9% to 3%
was not statistically significant. Preoperative MRI and PET/CT could in-
crease the proportion of stage IIIC patients with limited uterine disease,
and thus lower the risk for local recurrence as observed in our study, but
this needs to be confirmed in future studies. The PORTEC-3 trial recently
demonstrated improved OS and failure-free survival when combining
chemotherapy and radiotherapy compared to radiotherapy alone in
high-risk patients, mainly driven by improved results in stage III
patients and with an increased rate of adverse events and persisting
morbidity [23]. Adjuvant chemotherapy alone was not explored in
PORTEC-3, thus the available evidence today does not support a benefit
of adding radiotherapy when adjuvant chemotherapy constitutes the
management strategy for advanced stage endometrial cancer, again
reflected in the analysis of the present population based series.402Our retrospective study is limited in its inability to establish clear
cause-effect relationships, especially in evaluating contributions of dif-
ferent diagnostic methods towards a reduction of the overall rate of pa-
tients undergoing lymphadenectomy. We are however, at this time
satisfied to point out that the rate of lymphadenectomy can be reduced,
and that in our setting, no apparent detrimental effect is seen. Preoper-
ative risk grouping to tailor surgery depends on a high concordance be-
tween the diagnostic workup and final diagnosis. We have previously
shown that there is histological discordance between biopsy and hys-
terectomy specimen in 16%, and that theMRI diagnosis of cervical inva-
sion and deep myometrial invasion have an accuracy of 79%–89% and
61–68% respectively, and thus additional parameters are necessary to
optimize a selective lymphadenectomy algorithm [24,25]. Availability
of imaging modalities including MRI and PET differs between institu-
tions and they are not standard of care in many countries. Immunohis-
tochemical analysis of ER and PR however, carries little extra cost and is
potentially beneficial for clinics without access to advanced imaging.
Improvement of the selective lymphadenectomy algorithm with focus
on cost effectiveness is an important aim for future research.
Another potential bias is the shorter follow-up time for the patients
treated in the most recent time period. We have attempted to compen-
sate for this by choosing appropriate outcome for comparison. This is es-
pecially relevant for lymphadenectomy frequencies, where the most
recent group has a median follow-up time of 25 months. Data matura-
tion will enable a better estimate of the recurrence rate and survival of
low-stage patients not undergoing lymphadenectomy, and will be re-
ported when finalizing theMoMaTEC2 study. We were unable to retro-
spectively quantify treatment related complications in our study, as
Fig. 4. Kaplan-Meier survival curves showing survival outcome before and after omitting radiotherapy as adjuvant treatment for A) all patients. B) completely resected FIGO stage III
patients. C) Recurrence rate by site at 3 years in completely resected patients. Patients censored before 3 years not included. Statistical comparison of groups with chi-square. FIGO:
International Federation of Gynecology and Obstetrics.
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for prospective data on patient reported outcomes for different treat-
ment modalities, to better understand tolerability in short and
long term.
In conclusion, we present data from a population based endometrial
cancer cohort over the span of twodecades, and show that changing to a
strategy of individualized risk-based stratification for lymphadenec-
tomy does not affect survival outcomes negatively, when compared to
the previous practice based onmore frequent lymphadenectomy. Addi-
tionally, our data supports that adjuvant treatment without radiother-
apy is feasible with maintained survival and was even associated to
improved survival for stage III patients.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2020.12.002.
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